stockportfolio.pro
Stocks / LQDA vs PTCT
LQDA vs PTCT
Liquidia Corporation and PTC Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Liquidia Corporation (LQDA) | PTC Therapeutics, Inc. (PTCT) | |
|---|---|---|
| Market cap | $6.2B | $6.1B |
| Revenue (latest FY) | $158.32M | $1.73B |
| Net income (latest FY) | $-68.92M | $682.64M |
| Revenue growth (5y CAGR) | 192.5% | 35.4% |
| Net margin | -43.5% | 39.4% |
| Return on equity | -154.0% | -332.5% |
| P/E ratio | 410.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LQDA — free Open PTCT — freeFrequently asked questions
Which is bigger, LQDA or PTCT?
Liquidia Corporation is larger by market capitalization — $6.2B versus $6.1B.
Which grows faster, LQDA or PTCT?
Over the last five fiscal years, Liquidia Corporation grew revenue faster — 192.5%/yr versus 35.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.